All In Biotech

Free tool

FAERS Monitor: Columvi

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761309 or its brand name (Columvi, Glofitamab-Gxbm). Reports on generic versions are filed under their own applications.

Reports

2,709

Serious

2,487

92% of reports

Hospitalization

872

Death reported

781

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • cytokine release syndrome855
  • disease progression486
  • off label use325
  • death304
  • pyrexia221
  • neutropenia198
  • immune effector cell-associated neurotoxicity syndrome156
  • covid-19126
  • anaemia115
  • infection114
  • febrile neutropenia107
  • pneumonia102
  • drug ineffective96
  • thrombocytopenia95
  • diffuse large b-cell lymphoma recurrent78

Reports by year received

View as table
YearReports
20181
20196
20208
202160
2022161
2023293
2024639
2025690
2026851

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,450 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
cytokine release syndromeSignal855345.6326.4281,223
diffuse large b-cell lymphoma recurrentSignal78284.7227.821,001
immune effector cell-associated neurotoxicity syndromeSignal156210.0179.931,399
disease progressionSignal48632.029.514,595
febrile neutropeniaSignal10712.510.41,127
neutropeniaSignal19811.39.91,862
thrombocytopeniaSignal956.65.4448
infectionSignal1146.15.1486
covid-19Signal1265.64.7473
pyrexiaSignal2215.04.4706
anaemiaSignal1154.73.9332
off label useSignal3252.92.6415
deathSignal3042.72.5348
pneumoniaSignal1022.42.087
drug ineffective960.60.534

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.